| Released | Contributor | Author | Title | Pages | Price |
| 8-Feb-2010 | ValuEngine, Inc. |
N/A
| ValuEngine Industry Report for DRUGS | 18 |
$49 |
| 8-Feb-2010 | ValuEngine, Inc. |
N/A
| ValuEngine Detailed Valuation Report for SOMX | 13 |
$25 |
| 6-Feb-2010 | Pechala's Reports | Frantisek Pechala | SOMAXON PHARMACEUTICALS INC (SOMX=US) 12-months forecast | 1 |
$15 |
| 6-Feb-2010 | PriceTarget Research, Inc. |
N/A
| Drug Intelligence Monitor: overall outlook NEUTRAL - 25 new Leaders; 25 new Laggards. | 65 |
$20 |
| 6-Feb-2010 | Standard & Poor's STARS Report |
N/A
| Somaxon Pharmaceuticals | 7 |
$35 |
| 5-Feb-2010 | Pechala's Reports | Lubomir Pechala | SOMAXON PHARMACEUTICALS INC (SOMX=US) 2-weeks forecast | 1 |
$10 |
| 4-Feb-2010 | Ford Investor Services, Inc. |
N/A
| Value Graph: SOMAXON PHARMACE -- SOMX | 1 |
$4 |
| 4-Feb-2010 | Ford Investor Services, Inc. |
N/A
| Industry Value Graph: ARYX , DSCO , HEPH , ICGN , MSHL , OGXI , PIP , SOMX -- DRUGS | 3 |
$4 |
| 27-Jan-2010 | Directors Deals Ltd. | Company Snapshot | Company Snapshot - Somaxon Pharmaceuticals Inc | 1 |
$10 |
| 26-Jan-2010 | EconomicInvestor |
N/A
| "The Economy Matters" Report for SOMX: the economy's impact on SOMX's price and risk, featuring the powerful EconomicInvestor Star Rating | 6 |
$15 |
1.52% Nasdaq 0.00%
Research Reports
